Novasep is a global provider of cost-effective and sustainable manufacturing solutions for life sciences molecules. Novasep's unique offering includes process development services, purification equipment and turnkey processes, contract manufacturing services and complex active molecules.
GTP Technology is a contract research and development organization providing custom recombinant protein and process development services to support biopharmaceutical companies.
Novasep and GTP Technology announced on March 21st 2016 a partnership that combines their expertise in monoclonal antibodies (mAbs) production. The partners aim to facilitate the development of therapeutic and diagnostic candidates for European biopharmaceutical clients. This partnership offers biotech firms full CDMO services at all development stages from gene to end product.
GTP offers know-how in producing mAbs at the proof-of-concept /discovery and early clinical stages while Novasep provides expertise and plant facilities for late stage production. The mid-size capacity and full range of services the partners offer fit closely with customer demand regarding expertise and fast-track process development. The partnership particularly targets mAb production for orphan drugs, ADCs and diagnostics.
MAbs are known to be complex to produce. As both upstream and downstream production steps have improved over the last decade, progress towards high-titer cultivation broth and high efficiency in purification suites has changed the processing technologies. The state-of-the-art DSP platform, based on the BioSC® continuous chromatography system that Novasep has designed, specifically addresses these new production challenges. This technical offering complements the CMO services Novasep provides for mAb production.